Dylan Beynon is the founder of the ketamine-assisted therapy startup Mindbloom. He shares what they’ve learned so far from running nearly 703,000 guided ketamine sessions and how he’s been dealing with a recent Wall Street Journal hit piece attempting to discredit his company.
In this conversation, you can expect to learn:
* How 703,000+ ketamine sessions revealed what actually drives healing — their data on why music selection, journaling timing, and the 2-5 minute onset of injectable ketamine dramatically impact outcomes versus clinical IV settings
* The hidden war between Big Pharma and psychedelic medicine — how Johnson & Johnson created an 88x more expensive version of ketamine, and why Mindbloom is suing the Wall Street Journal for defamation
* Why "super well-being", not just "not sick" should be medicine's goal — the shift from disease management to human flourishing, and how psychedelics can unlock 100x improvements in life quality most people don't realize are possible
* The real reason IV ketamine is considered "gold standard" (and why it shouldn't be) — how anesthesiologists accidentally created inferior protocols, why injectable beats IV for therapeutic use
